PreventionGenetics is proud to partner with biopharmaceutical companies to offer sponsored testing programs to patients who qualify. Through these partnerships we are paving the way for more timely and effective intervention--with a shared goal of improving lives through genetic testing.

AAKP

No-Cost Genetic Testing for Fabry Disease - The AAKP Fabry Disease Diagnostic Testing and Education Project

In partnership with the American Association of Kidney Patients (AAKP) and Emory University, this program provides complimentary Clinical DNA testing for this rare genetic disease can help patients receive an early diagnosis and access to treatment. This AAKP program is supported by educational donations from Amicus Therapeutics and Sanofi-Genzyme, Inc.

More Information
Akouos Resonate

No-Charge Genetic Testing and Counseling Program for Sensorineural Hearing Loss

In partnership with Akouos, Inc., a wholly owned subsidiary of Eli Lilly, the Resonate® program offers no-charge genetic testing and counseling for sensorineural hearing loss. Resonate uses a comprehensive panel of nearly 300 genes to potentially determine whether there is an underlying genetic cause of hearing loss. This program is available for providers in the U.S., Brazil, and Mexico.

More Information
Biogen FA Identified

No-Cost Genetic Testing Program for Friedreich Ataxia (FA)

Sponsored by Biogen, this program provides no-cost genetic testing for Friedreich ataxia(FA), a neurodegenerative disease characterized by progressive ataxia (ataxic gait and limbs), dysarthria, dysphagia, decreased proprioception, distal muscle weakness, peripheral sensory neuropathy, absent lower limb tendon reflexes, spasticity, scoliosis, pes cavus, and hypertrophic cardiomyopathy. No-cost FA testing is available for patients 16 years of age or older, suspected of or have a clinical diagnosis of FA, and be a resident of the United States or Puerto Rico. The test must be ordered by a qualified healthcare provider.

More Information
Calcilytix

DetectHypopara™ Sponsored Testing Program

In partnership with Calcilytix Therapeutics, this program provides physicians with access to no-cost genetic testing for patients, who have a clinical diagnosis of non-surgical hypoparathyroidism or hypocalcemia suspected to be of genetic cause, or meet other eligibility criteria for testing. This program is available for patients and providers in the US & Canada.

More Information
Decibel Therapeutics

Amplify™ Sponsored Testing Program

In partnership with Decibel Therapeutics, Amplify™ is a no-charge genetic testing program for children diagnosed with auditory neuropathy. Amplify™ strives to remove barriers to genetic diagnosis for patients born with auditory neuropathy.

More Information
Foundation for Fighting Blindness Logo Spark Logo

My Retina Tracker Program

The My Retina Tracker Genetic Testing Program offers individuals with a clinical diagnosis of an Inherited Retinal Disease (IRD) access to high-quality diagnostic testing, genetic counseling, and connection to a growing IRD registry at no cost to the patient. Targeted familial variant testing is also available to blood relatives of individuals who receive a positive result through the Program. The Foundation Fighting Blindness, a nonprofit organization dedicated to finding treatments for IRD, and Spark Therapeutics sponsor the Program.

More Information
Inozyme Pharma

No-Cost Genetic Testing Program for Rare Calcification Disorders

ENPP1 and ABCC6 Deficiencies

This program sponsored by Inozyme Pharma offers global, no-cost genetic testing for the Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP binding cassette subfamily C member 6 (ABCC6) genes. These genes are implicated in two rare, severe, debilitating calcification disorders: ENPP1 Deficiency and ABCC6 Deficiency. Both these disorders can manifest as generalized arterial calcification of infancy (GACI) type 1 in infancy and then autosomal recessive hypophosphatemic rickets type 2 (ARHR2) in the case of ENPP1 Deficiency or Pseudoxanthoma elasticum (PXE) in the case of ABCC6 Deficiency post infancy.

More Information

ABCC6 Deficiency Only

This program sponsored by Inozyme Pharma offers global, no-cost genetic testing for the ABCC6 gene associated with Pseudoxanthoma Elasticum (PXE). This no charge testing is being offered to patients who meet testing eligibility criteria and must be ordered by a qualified healthcare provider.

More Information
Ionis

No-Cost Genetic Testing Program for Amyotrophic Lateral Sclerosis (ALS)

In partnership with Ionis Pharmaceuticals, this program provides no-cost genetic testing for amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by motor neuron impairment in the cortex, brain stem, and spinal cord. No-cost ALS testing is available for patients with a clinical diagnosis or family history of ALS and is being offered to residents of the U.S. and Canada who meet testing eligibility criteria. The test must be ordered by a qualified healthcare provider.

More Information

No-Cost Genetic Testing Program for Familial Chylomicronemia Syndrome (FCS)

In partnership with Ionis Pharmaceuticals, this program provides no-cost genetic testing for familial chylomicronemia syndrome (FCS), a genetic condition which is characterized by high plasma triglyceride levels resulting from improper breakdown of chylomicron lipoproteins by the LPL enzyme. No-cost FCS testing is available for patients with a clinical diagnosis of FCS and is being offered to residents of the US and Canada who meet testing eligibility criteria. The test must be ordered by a qualified healthcare professional.

More Information
Krystal

Decode DEB Sponsored Testing Program

In partnership with Krystal Biotech, Inc., this program offers no-charge genetic testing for patients with suspected dystrophic epidermolysis bullosa (DEB) and qualifying family members of patients diagnosed with DEB. This program is available to patients in the United States, including Puerto Rico.

More Information
Mirum

Movement Disorder Genetic Test Program

Mirum Pharmaceuticals has partnered with PreventionGenetics to offer a no-cost genetic testing program to help identify the genetic cause of movement disorders through a 938-gene next generation sequencing panel. This program is available to residents in North America (US and Canada) who meet eligibility criteria and must be ordered by a qualified healthcare provider.

More Information

No-Cost Patient Genetic Testing Program for Cholestasis

Mirum Pharmaceuticals has partnered with PreventionGenetics to offer a no-cost genetic testing program to help identify the genetic cause of cholestasis through a 77-gene panel. This program is available to US resident who meet eligibility criteria and must be ordered by a qualified healthcare provider.

More Information

Behind the Blur: No-Cost Patient Genetic Testing Program for Early-Onset Bilateral Cataracts

Mirum Pharmaceuticals has partnered with PreventionGenetics to offer a no-cost genetic testing program to help identify the genetic cause of early onset, often bilateral, cataracts through a 66-gene panel. This program is available for patients in the US who meet eligibility criteria and must be ordered by a qualified healthcare provider.

More Information

No-Cost Patient Testing Program for Peroxisome Biogenesis Disorder - Zellweger Spectrum Disorder (PBD-ZSD)

Mirum Pharmaceuticals has partnered with PreventionGenetics to offer a no-cost genetic testing program to help identify peroxisome biogenesis disorder-Zellweger spectrum disorder (PBD-ZSD) through a 13-gene panel. This program is available for patients in the US who meet eligibility criteria and must be ordered by a qualified healthcare provider.

More Information

No-Cost Genetic Testing Program for States Initiating Newborn Screening for X-linked Adrenoleukodystrophy (X-ALD)

Mirum Pharmaceuticals has partnered with PreventionGenetics to offer a no-cost genetic testing program to help identify peroxisome biogenesis disorder-Zellweger spectrum disorder (PBD-ZSD) and other disorders within the states offering X-ALD newborn screening programs. Testing will be offered to children who screened positive for X-ALD on initial state newborn screen but negative for the disease after further evaluation.

More Information
PassageBio FTD

Frontotemporal Dementia Sponsored Testing Program

In partnership with Passage Bio, this program provides physicians access to no-cost genetic testing for patients, who are suspected of having frontotemporal dementia (FTD), a clinically heterogeneous syndrome due to the progressive degeneration and atrophy of various regions of the frontal and temporal lobes of the brain.

More Information
Pharming navigateAPDS

Sponsored Genetic Testing Program for Activated PI3K Delta Syndrome (APDS)

Pharming Healthcare, Inc. has partnered with PreventionGenetics to provide navigateAPDS, a sponsored genetic testing program for Activated PI3K Delta Syndrome (APDS), a progressive primary immunodeficiency, characterized by vulnerability to repeat infections, immune dysregulation, lymphadenopathy, splenomegaly or hepatomegaly, autoimmune cytopenias, and even lymphoma (Elkaim et al. 2016. PubMed ID: 27221134). navigateAPDS is available for patients who meet program criteria and is being offered to residents of the United States, Puerto Rico, and Canada. The test must be ordered by a qualified healthcare provider.

More Information
Rhythm Pharmaceuticals

No-charge Sponsored Testing Program for Rare Genetic Diseases of Obesity

This program is sponsored by Rhythm Pharmaceuticals and is intended to expand access to genetic testing for individuals with a rare genetic disease of obesity. The test sequences 79 genes associated with rare genetic diseases of obesity. Tests may only be ordered by licensed US or Canadian healthcare providers and patients must reside in the United States, its territories, or Canada.

More Information

POMC/PCSK1/LEPR Companion Diagnostic (CDx) Panel

This test is a companion diagnostic device intended to select adult and pediatric patients 6 years of age and older who have obesity and certain variants in POMC, PCSK1, or LEPR genes for treatment with IMCIVREE® (setmelanotide) in accordance with the approved therapeutic product labeling.

More Information
UCB logo

No-Cost Genetic Testing Program for Thymidine Kinase 2 Deficiency

In partnership with UCB, this No-Cost Genetic Testing Program is available to individuals with a suspected or clinical diagnosis of Thymidine Kinase 2 Deficiency (TK2d) is a rare, inherited, and debilitating myopathic mitochondrial disease that is often fatal and can present at any age. It is a mitochondrial DNA depletion disorder.

More Information